Cerenome secures in-network agreement with Florida Blue
Cerenome, Inc. says it secured an in-network agreement with Florida Blue for Cnside® CSF tumor cell enumeration and molecular profile tests.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Cerenome secures Florida Blue in-network CNSide CSF test agreement
Cerenome’s CNSide Diagnostics says its first in-network payer agreement with Florida Blue will add CNSide’s CSF molecular profile tests alongside tumor cell enumeration, expanding contracted access to about 164 million covered lives.